Blood Pressure Responses to Noncardiovascular Drugs in Development and Therapeutic Use

  • J. Rick Turner
  • Dilip R. Karnad
  • Snehal Kothari


This chapter focuses on unintended drug-induced blood pressure responses. While both increases and decreases are legitimate areas of investigation (Kane-Gill et al. 2014; Kennelly and Esaian 2013), our attention falls on increases. As was noted in Sect.  3.4.4, high blood pressure is authoritative regarded as the greatest threat to the global burden of disease (Horton 2013; Das and Samarasekera 2013; Lim et al. 2013). As hypertension has been studied across several decades, we have learned that there are multiple ways in which increased blood pressure may occur (see Frohlich 1977; Page 1982; Dustan 1990; Harrison 2013). It has now also become clear that noncardiovascular drugs can lead to off-target increases in blood pressure and can also do so via a variety of mechanisms of action. As Grossman and Messerli (2012) observed, “Some agents cause either sodium retention or extracellular volume expansion, or activate directly or indirectly the sympathetic nervous system. Other substances act directly on arteriolar smooth muscle or do not have a defined mechanism of action. Some medications that usually lower BP may paradoxically increase BP, or an increase in pressure may be encountered after their discontinuation.”


Blood Pressure Monitoring Blood Pressure Increase Ambulatory Blood Pressure Monitoring Blood Pressure Response Heart Outcome Prevention Evaluation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Authier S, Pugsley MK, Curtis MJ (2015) Haemodynamic assessment in safety pharmacology. In: Pugsley MK, Curtis MJ (eds) Principles of safety pharmacology: handbook of experimental pharmacology 229. Springer, Berlin, pp 221–241CrossRefGoogle Scholar
  2. Authier S, Tanguay JF, Fournier S et al (2008) Conscious and anesthetized non-human primate safety pharmacology models: hemodynamic sensitivity comparison. J Pharmacol Toxicol Methods 58:94–98CrossRefPubMedGoogle Scholar
  3. Bhide AA, Digesu GA, Fernando R et al (2012) Use of mirabegron in treating overactive bladder. Int Urogynecol J 23:1345–1348CrossRefPubMedGoogle Scholar
  4. Das P, Samarasekera U (2013) The story of GBD 2010: a “super-human” effort. Lancet 380:2067–2070CrossRefGoogle Scholar
  5. Dustan HP (1990) Irvine Page lecture. Legacies of Irvine H. Page. J Hypertens Suppl 8:S29–S34PubMedGoogle Scholar
  6. Franklin SS, Thijs L, Hansen TW et al (2013) White-coat hypertension: new insights from recent studies. Hypertension 62:982–987CrossRefPubMedGoogle Scholar
  7. Frohlich ED (1977) Essential hypertension. Pathophysiological mechanisms and therapy. Arch Intern Med 137:772–775CrossRefPubMedGoogle Scholar
  8. Grossman E, Messerli FH (2012) Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 125:14–22CrossRefPubMedGoogle Scholar
  9. Grossman A, Messerli FH, Grossman E (2015) Drug induced hypertension: an unappreciated cause of secondary hypertension. Eur J Pharmacol 763:15–22CrossRefPubMedGoogle Scholar
  10. Harrison DG (2013) The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. J Am Soc Hypertens 7:68–74CrossRefPubMedPubMedCentralGoogle Scholar
  11. Horton R (2013) GBD 2010: understanding disease, injury, and risk. Lancet 380:2053–2054CrossRefGoogle Scholar
  12. Kane-Gill SL, LeBlanc JM, Dasta JF, Devabhakthuni S, Critical Care Pharmacotherapy Trials Network (2014) A multicenter study of the point prevalence of drug-induced hypotension in the ICU. Crit Care Med 42:2197–2203CrossRefPubMedGoogle Scholar
  13. Kennelly C, Esaian D (2013) Drug-induced cardiovascular adverse events in the intensive care unit. Crit Care Nurs Q 36:323–334CrossRefPubMedGoogle Scholar
  14. Krakoff LR (2006) Cost-effectiveness of ambulatory blood pressure: a reanalysis. Hypertension 47:29–34CrossRefPubMedGoogle Scholar
  15. Lim SS, Vos T, Flaxman AD et al (2013) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2224–2260CrossRefGoogle Scholar
  16. Lovibond K, Jowett S, Barton P et al (2011) Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modeling study. Lancet 378:1219–1230CrossRefPubMedGoogle Scholar
  17. NICE (National Institute for Health and Care Excellence) (2011) Clinical guideline 127. Hypertension: clinical management of primary hypertension in adults. August 2011. Available at: Accessed 27 Nov 2015
  18. O’Brien E (2011a) The value of 24-hour blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. Hot Topics Hypertens 4:7–23Google Scholar
  19. O’Brien E (2011b) 24-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J Intern Med 269:478–495CrossRefPubMedGoogle Scholar
  20. O’Brien E (2012) First Thomas Pickering memorial lecture ambulatory blood pressure measurement is essential for the management of hypertension. J Clin Hypertens (Greenwich) 14:836–847CrossRefGoogle Scholar
  21. O’Brien E, Turner JR (2013) Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 15:55–62CrossRefGoogle Scholar
  22. Page IH (1982) The mosaic theory 32 years later. Hypertension 4:177CrossRefPubMedGoogle Scholar
  23. Pickering TG, James GD, Boddie C et al (1988) How common is white coat hypertension? JAMA 259:225–228CrossRefPubMedGoogle Scholar
  24. Sager P, Heilbraun J, Turner JR et al (2013) Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J 165:477–488CrossRefPubMedGoogle Scholar
  25. Siu AL, U.S. Preventive Services Task Force (2015) Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 163:778–786CrossRefPubMedGoogle Scholar
  26. Stockbridge S (2011) Letter to the editor: ABPM part of FDA reviews. Drug Inf J 45:567CrossRefGoogle Scholar
  27. Svensson P, de Faire U, Sleight P et al (2001) Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38:E28–E32CrossRefPubMedGoogle Scholar
  28. Virdis A, Ghiadoni L, Taddei S, Italian Society of Hypertension (SIIA) (2014) Clinical management of drug-induced hypertension: 2013 practical recommendations of the Italian Society of Hypertension (SIIA). High Blood Press Cardiovasc Prev 21:77–79CrossRefPubMedGoogle Scholar
  29. Williams B (2000) The renin-angiotensin system and cardiovascular disease: hope or hype? J Renin Angiotensin Aldosterone Syst 1:142–146CrossRefPubMedGoogle Scholar
  30. Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153CrossRefPubMedGoogle Scholar

Further Reading

  1. Albrecht M, Henke J, Tacke S, Markert M, Guth B (2014) Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats. BMC Vet Res 10:198CrossRefPubMedPubMedCentralGoogle Scholar
  2. Amouzadeh HR, Engwall MJ, Vargas HM (2015) Safety pharmacology evaluation of biopharmaceuticals. Handb Exp Pharmacol 229:385–404CrossRefPubMedGoogle Scholar
  3. Barter PJ, Caulfield M, Eriksson M et al (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122CrossRefPubMedGoogle Scholar
  4. Bhatt S, Foote S, Smith A, Butler P, Steidl-Nichols J (2015) A non-human primate model for investigating drug-induced risk of orthostatic hypotension and sympathetic dysfunction: preclinical correlate to a clinical test. J Pharmacol Toxicol Methods 73:49–55CrossRefPubMedGoogle Scholar
  5. Blankfield RP (2012) Blood pressure, fluid retention and the cardiovascular risk of drugs. Future Cardiol 8:489–493CrossRefPubMedGoogle Scholar
  6. Breaux-Shropshire TL, Judd E, Vucovich LA, Shropshire TS, Singh S (2015) Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes. Integr Blood Press Control 8:43–49CrossRefPubMedPubMedCentralGoogle Scholar
  7. Campbell NR, Gelfer M, Stergiou GS et al (2016) A call to regulate manufacture and marketing of blood pressure devices and cuffs: a position statement from the World Hypertension League, International Society of Hypertension and Supporting Hypertension Organizations. J Clin Hypertens (Greenwich) 18:378–380Google Scholar
  8. Caruso A, Frances N, Meille C et al (2014) Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: methods and examples in drug development. J Pharmacol Toxicol Methods 70:73–85CrossRefPubMedGoogle Scholar
  9. Choi HY, Park HC, Ha SK (2015) Salt sensitivity and hypertension: a paradigm shift from kidney malfunction to vascular endothelial dysfunction. Electrolyte Blood Press 13:7–16CrossRefPubMedPubMedCentralGoogle Scholar
  10. Choure BK, Gosavi D, Nanotkar S (2014) Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study. Indian J Pharmacol 46:493–497CrossRefPubMedPubMedCentralGoogle Scholar
  11. Collins TA, Bergenholm L, Abdulla T et al (2015) Modeling and simulation approaches for cardiovascular function and their role in safety assessment. CPT Pharmacometrics Syst Pharmacol 4:e00018CrossRefPubMedPubMedCentralGoogle Scholar
  12. Daskalopoulou SS, Rabi DM, Zarnke KB, Canadian Hypertension Education Program et al (2015) The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 31:549–568CrossRefPubMedGoogle Scholar
  13. Dolan E, O’Brien E (2015) Is it daily, monthly, or yearly blood pressure variability that enhances cardiovascular risk? Curr Cardiol Rep 17:93CrossRefPubMedGoogle Scholar
  14. Draman MS, Dolan E, van der Poel L et al (2015) The importance of night-time systolic blood pressure in diabetic patients: Dublin Outcome Study. J Hypertens 33:1373–1377CrossRefPubMedGoogle Scholar
  15. Eghbalibabadi M, Ashouri E (2014) Comparison of the effects of two teaching methods on the nursing students’ performance in measurement of blood pressure. Iran J Nurs Midwifery Res 19:381–384PubMedPubMedCentralGoogle Scholar
  16. Egner B (2015) High definition oscillometry: non-invasive blood pressure measurement and pulse wave analysis. Handb Exp Pharmacol 229:243–264CrossRefPubMedGoogle Scholar
  17. Ewart L, Aylott M, Deurinck M et al (2014) The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. Toxicol Sci 142:427–435CrossRefPubMedGoogle Scholar
  18. Gazibara T, Rancic B, Maric G et al (2015) Medical students, do you know how to measure blood pressure correctly? Blood Press Monit 20:27–31CrossRefPubMedGoogle Scholar
  19. Gintant G (2015) In vitro early safety pharmacology screening: perspectives related to cardiovascular safety. Handb Exp Pharmacol 229:47–64CrossRefPubMedGoogle Scholar
  20. Grassi G, Mark A, Esler M (2015) The sympathetic nervous system alterations in human hypertension. Circ Res 116:976–990CrossRefPubMedPubMedCentralGoogle Scholar
  21. Hall JE, do Carmo JM, Da Silva AA, Wang Z, Hall ME (2015) Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 116:991–1006CrossRefPubMedPubMedCentralGoogle Scholar
  22. Harvey A, Montezano AC, Touyz RM (2015) Vascular biology of ageing: implications in hypertension. J Mol Cell Cardiol 83:112–121CrossRefPubMedPubMedCentralGoogle Scholar
  23. Imai Y (2014) Clinical significance of home blood pressure and its possible practical application. Clin Exp Nephrol 18:24–40CrossRefPubMedGoogle Scholar
  24. Imai Y, Obara T, Asamaya K, Ohkubo T (2013) The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. Hypertens Res 36:661–672CrossRefPubMedGoogle Scholar
  25. Imai Y, Hosaka M, Elnagar N, Satoh M (2014) Clinical significance of home blood pressure measurements for the prevention and management of high blood pressure. Clin Exp Pharmacol Physiol 41:37–45CrossRefPubMedGoogle Scholar
  26. Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ (2012) On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs 72:491–507CrossRefPubMedGoogle Scholar
  27. Juhanoja E, Niiranen TJ, Johansson JK, Puukka PJ, Jula AM (2015) Agreement between ambulatory, home and office blood pressure variability. J Hypertens 33(Suppl 1):e42–e43CrossRefPubMedGoogle Scholar
  28. Kang YY, Li Y, Huang QF et al (2015) Accuracy of home versus ambulatory blood pressure monitoring in the diagnosis of white-coat and masked hypertension. J Hypertens 33:1580–1587CrossRefPubMedGoogle Scholar
  29. Kassel LE, Odum LE (2015) Our own worst enemy: pharmacologic mechanisms of hypertension. Adv Chronic Kidney Dis 22:245–252CrossRefPubMedGoogle Scholar
  30. Kjeldsen SE, Aksnes TA, Ruilope LM (2014) Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D 14:31–43CrossRefPubMedPubMedCentralGoogle Scholar
  31. Kjeldsen S, Feldman RD, Lisheng L et al (2014) Updated national and international hypertension guidelines: a review of current recommendations. Drugs 74:2033–2051CrossRefPubMedPubMedCentralGoogle Scholar
  32. Klein SK, Redfern WS (2015) Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: conference report. J Pharmacol Toxicol Methods 76:1–6CrossRefPubMedGoogle Scholar
  33. Kremer JJ, Bills AJ, Hanke NJ et al (2015) Evaluation of cardiovascular changes in dogs administered three positive controls using jacketed external telemetry-blood pressure (JET-BP). J Pharmacol Toxicol Methods 75:27–37, May 20CrossRefPubMedGoogle Scholar
  34. Lee J, Chee Y, Kim I et al (2015) High-fidelity digital recording and playback sphygmomanometry system: device description and proof of concept. Blood Press Monit 20:266–272CrossRefPubMedGoogle Scholar
  35. Martel E, Egner B, Brown SA et al (2013) Comparison of high-definition oscillometry, a non-invasive technology for arterial blood pressure measurement, with a direct invasive method using radio-telemetry in awake healthy cats. J Feline Med Surg 15:1104–1113CrossRefPubMedGoogle Scholar
  36. McKee J, Daller J, Baumgartner B, Pettinger S (2014) Evaluation of the sensitivity of a new fully implantable telemetry device and the importance of simultaneously measuring cardiac output and left ventricular pressure. J Pharmacol Toxicol Methods 69:229–236CrossRefPubMedGoogle Scholar
  37. Mounier-Vehier C, Boudghène F, Claisse G, Delsart P (2015) Iatrogenic and drug-induced hypertension. Rev Prat 65:809–816PubMedGoogle Scholar
  38. Nishimoto M, Fujita T (2015) Renal mechanisms of salt-sensitive hypertension: contribution of two steroid receptor-associated pathways. Am J Physiol Renal Physiol 308:F377–F387CrossRefPubMedGoogle Scholar
  39. O’Brien E (2016) Why is it that we continue to deny patients ambulatory blood pressure monitoring? Hypertension 67:484–487PubMedGoogle Scholar
  40. O’Brien E (2016) Prognostic value of ambulatory blood pressure monitoring in obese patients. J Clin Hypertens (Greenwich) 18:119–120CrossRefGoogle Scholar
  41. O’Brien E (2016) Why is it so difficult to influence the clinical management of hypertension? J Clin Hypertens (Greenwich) [Epub ahead of print]Google Scholar
  42. O’Brien E, Dolan E, Atkins N (2015) Failure to provide ABPM to all hypertensive patients amounts to medical ineptitude. J Clin Hypertens (Greenwich) 17:462–465CrossRefGoogle Scholar
  43. Omboni S, Palatini P, Parati G, Working Group on Blood Pressure Monitoring of the Italian Society of Hypertension (2015) Standards for ambulatory blood pressure monitoring clinical reporting in daily practice: recommendations from the Italian Society of Hypertension. Blood Press Monit 20:241–244CrossRefPubMedGoogle Scholar
  44. Paolasso JA, Crespo F, Arias V et al (2015) Clinical practice of ambulatory versus home blood pressure monitoring in hypertensive patients. Blood Press Monit 20:241–244CrossRefGoogle Scholar
  45. Parati G, Stergiou G, O’Brien E, European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability et al (2014) European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 32:1359–1366CrossRefPubMedGoogle Scholar
  46. Rader DJ (2007) Illuminating HDL: is it still a viable therapeutic target? N Engl J Med 357:2180–2183CrossRefPubMedGoogle Scholar
  47. Ray EC, Rondon-Berrios H, Boyd CR, Kleyman TR (2015) Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension. Adv Chronic Kidney Dis 22:179–184CrossRefPubMedPubMedCentralGoogle Scholar
  48. Rysnik MK, Cripps P, Iff I (2013) A clinical comparison between a non-invasive blood pressure monitor using high definition oscillometry (Memodiagnostic MD 15/90 Pro) and invasive arterial blood pressure measurement in anaesthetized dogs. Vet Anaesth Analg 40:503–511CrossRefPubMedGoogle Scholar
  49. Sarazan RD (2014) Cardiovascular pressure measurement in safety assessment studies: technology requirements and potential errors. J Pharmacol Toxicol Methods 70:210–223CrossRefPubMedGoogle Scholar
  50. Segal L, Roger V, Williams C, Destexhe E, Garçon N (2015) Effects of adjuvant systems on the cardiovascular and respiratory functions in telemetered conscious dogs and anaesthetised rats. Regul Toxicol Pharmacol 73:116–125CrossRefPubMedGoogle Scholar
  51. Stephan D, Gaertner S, Cordeanu EM (2015) A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults. Arch Cardiovasc Dis 108:453–459CrossRefPubMedGoogle Scholar
  52. Stergiou GS, Ntineri A (2015) The optimal schedule for self-home blood pressure monitoring. J Hypertens 33:693–697CrossRefPubMedGoogle Scholar
  53. Tokunaga J, Takamura N, Ogata K et al (2014) An advanced objective structured clinical examination using patient simulators to evaluate pharmacy students’ skills in physical assessment. Am J Pharm Educ 78:184CrossRefPubMedPubMedCentralGoogle Scholar
  54. Viera AJ, Lin FC, Tuttle LA et al (2014) Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit 19:208–215CrossRefPubMedPubMedCentralGoogle Scholar
  55. Viera AJ, Tuttle LA, Voora R, Olsson E (2015) Comparison of patients’ confidence in office, ambulatory, and home blood pressure measurements as methods of assessing for hypertension. Blood Press Monit 20:335–340CrossRefPubMedPubMedCentralGoogle Scholar
  56. Viera AJ, Tuttle L, Zeng J (2016) Dollars and discomfort: what will people be willing to give for better blood pressure assessment? J Clin Hypertens (Greenwich) 18:422–423Google Scholar
  57. Virdis A, Ghiadoni L, Taddei S, Italian Society of Hypertension (SIIA) (2014) Clinical management of drug-induced hypertension: 2013 Practical Recommendations of the Italian Society of Hypertension (SIIA). High Blood Press Cardiovasc Prev 21:77–79CrossRefPubMedGoogle Scholar
  58. Weber MA, Schiffrin EL, White WB et al (2014) Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 16:14–26CrossRefGoogle Scholar
  59. Weber MA, Turner JR (2016) Ambulatory blood pressure monitoring: new directions and uncertainties arise from the United States Preventive Services Task Force recommendation on the diagnosis of hypertension. J Clin Hypertens (Greenwich) 18:173–175Google Scholar
  60. Yuan H, Zhao J, Guo J (2014) Comparison of freely-moving telemetry Chinese Miniature Experiment Pigs (CMEPs) to beagle dogs in cardiovascular safety pharmacology studies. J Pharmacol Toxicol Methods 70:19–28CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • J. Rick Turner
    • 1
  • Dilip R. Karnad
    • 2
  • Snehal Kothari
    • 3
  1. 1.Cardiac Safety Services QuintilesDurhamUSA
  2. 2.Research TeamCardiac Safety Services QuintilesMumbaiIndia
  3. 3.Cardiac Safety Services Global HeadCardiac Safety Center of Excellence QuintilesMumbaiIndia

Personalised recommendations